Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drug.

Competition assay Flow cytometry Suramin analogues Trypanocidal activity Trypanosoma brucei

Journal

Experimental parasitology
ISSN: 1090-2449
Titre abrégé: Exp Parasitol
Pays: United States
ID NLM: 0370713

Informations de publication

Date de publication:
19 Mar 2024
Historique:
received: 14 12 2023
revised: 22 02 2024
accepted: 18 03 2024
medline: 22 3 2024
pubmed: 22 3 2024
entrez: 21 3 2024
Statut: aheadofprint

Résumé

Suramin was the first effective drug for the treatment of human African sleeping sickness. Structural analogues of the trypanocide have previously been shown to be potent inhibitors of several enzymes. Therefore, four suramin analogues lacking the methyl group on the intermediate rings and with different regiochemistry of the naphthalenetrisulphonic acid groups and the phenyl rings were tested to establish whether they exhibited improved antiproliferative activity against bloodstream forms of Trypanosomes brucei compared to the parent compound. The four analogues exhibited low trypanocidal activity and weak inhibition of antitrypanosomal activity of suramin in competition experiments. This indicates that the strong trypanocidal activity of suramin is most likely due to the presence of methyl groups on its intermediate rings and to the specific regiochemistry of naphthalenetrisulphonic acid groups. These two structural features are also likely to be important for the inhibition mechanism of suramin because DNA distribution and nucleus/kinetoplast configuration analyses suggest that the analogues inhibit mitosis while suramin inhibits cytokinesis.

Identifiants

pubmed: 38513971
pii: S0014-4894(24)00047-X
doi: 10.1016/j.exppara.2024.108744
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108744

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors declare that there were no commercial or financial interests or any other conflicts of interest.

Auteurs

Dietmar Steverding (D)

Bob Champion Research and Education Centre, Norwich Medical School, University of East Anglia, Norwich, United Kingdom. Electronic address: d.steverding@uea.ac.uk.

Ryan A J Tinson (RAJ)

Bob Champion Research and Education Centre, Norwich Medical School, University of East Anglia, Norwich, United Kingdom; School of Pharmacy, University of East Anglia, Norwich, United Kingdom.

Monica Piras (M)

Target Discovery Institute, University of Oxford, Oxford, United Kingdom.

Stephen P Wren (SP)

Department of Chemical and Pharmaceutical Sciences, Kingston University London, Kingston Upon Thames, United Kingdom.

Stuart A Rushworth (SA)

Bob Champion Research and Education Centre, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.

Mark Searcey (M)

School of Pharmacy, University of East Anglia, Norwich, United Kingdom.

Linda Troeberg (L)

Bob Champion Research and Education Centre, Norwich Medical School, University of East Anglia, Norwich, United Kingdom.

Classifications MeSH